Arcturus Therapeutics (NASDAQ:ARCT) and GlobeImmune (OTCMKTS:GBIM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arcturus Therapeutics and GlobeImmune, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics 0 0 5 1 3.17
GlobeImmune 0 0 0 0 N/A

Arcturus Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 56.52%. Given Arcturus Therapeutics’ higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than GlobeImmune.

Institutional and Insider Ownership

12.9% of Arcturus Therapeutics shares are owned by institutional investors. 0.0% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 23.5% of GlobeImmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Arcturus Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, GlobeImmune has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.


This table compares Arcturus Therapeutics and GlobeImmune’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcturus Therapeutics -50.32% -112.75% -30.62%
GlobeImmune N/A N/A N/A

Earnings and Valuation

This table compares Arcturus Therapeutics and GlobeImmune’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcturus Therapeutics $15.75 million 10.42 -$21.78 million ($2.16) -5.32
GlobeImmune N/A N/A N/A N/A N/A

GlobeImmune has lower revenue, but higher earnings than Arcturus Therapeutics.


Arcturus Therapeutics beats GlobeImmune on 6 of the 10 factors compared between the two stocks.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.